Free press releases distribution network?

Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Phillip K Weck, Vice President of Centocor to Speak At 9th Cytokines Conference January 27 in San Diego, California - Phillip K. Weck, will give a featured presentation on “Anti-TNF Therapies: A Case Study of Golimumab Global Development & Life Cycle Management” at the at 9th Cytokines & Inflammation Conference
Phillip K Weck, Vice President of Centocor to Speak At 9th Cytokines Conference January 27 in San Diego, California

 

PRZOOM - /newswire/ - Monrovia, CA, United States, 2010/12/08 - Phillip K. Weck, will give a featured presentation on “Anti-TNF Therapies: A Case Study of Golimumab Global Development & Life Cycle Management” at the at 9th Cytokines & Inflammation Conference.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Phillip K. Weck, Vice President & Compound Development Team Leader at Centocor will give a featured presentation on “Anti-TNF Therapies: A Case Study of Golimumab Global Development & Life Cycle Management” at the at 9th Cytokines & Inflammation Conference to be held in San Diego, CA on January 27-28, 2011 by GTCbio.

Golimumab was the first anti-TNF approved for three indications simultaneously in 2009 and will be the first to offer both SC and IV routes of administration. Golimumab significantly improves signs and symptoms, physical function, and health-related quality of life in subjects affected by rheumatologic disorders. Treatment with golimumab also reduces the rate of progression of structural damage associated with RA and PsA. Regulatory dossiers for these indications are submitted in over 50 countries globally with approvals in approximately 38 countries.

Golimumab is currently offered in the SmartJect® auto injector and UltraSafe® pre-filled syringes. SmartJect® and monthly dosing distinguish golimumab from other anti-TNFs and provide patient friendly administration of the product.

The 9th Cytokine and Inflammation Conference will cover ever-important topics such as the TNF family, the inflammasome, chemokines, costimulation and innate immunity. In addition, timely coverage will be devoted to areas of current rapid expansion, such as the IL-17 and Th17 fields and JAK/STAT kinases, at a time when phase 2 and even phase 3 studies are being conducted and reported in these areas. Intriguing recently discovered cytokines, such as IL-25, novel alarmins and novel IL-1 family members will also be covered.

As usual, poster sessions and opportunities for networking will complement the great roster of distinguished speakers. The organizations participating are a great selection of innovative medical organizations from academia (NIH, UCLA, UCSD, Cleveland Clinic, La Jolla Institute, Virginia Commonwealth U, U Mass, City of Hope, Scripps, Barts and the London), industry (Amgen, Pfizer, MedImmune, Novartis, Centocor/Johnson and Johnson, Biogen Idec, Incyte, Genentech, Genzyme, Chemocentryx) and, last but not -by any means- least, the US FDA.

With a 50-50 mix of academic and industry authoritative experts, the conference will cover many current and relevant aspects of cytokine biology from their respective angles. If your work focuses on basic, translational or full development cytokine biology and its applicability to human health, I encourage you to attend this conference which promises to be a fertile ground for scientific exchange and collaboration.

For more information, visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Phillip K Weck, Vice President of Centocor to Speak At 9th Cytokines Conference January 27 in San Diego, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: GTCbio.com 
626-256-6405
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Deb Sheppard - Medium Psychic Author Speaker

Visit  MagLar, Inc.

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today